Qualification of an Environmental Monitoring Program - 1.
Selection/Justification of Sample Sites Scott Sutton, Ph.D.
http://www.linkedin.com/in/scottvwsutton
This article first appeared in the PMF Newsletter of
August, 2009 and is protected by copyright to PMF. It appears here with permission.
Introduction
The microbiology department plays a critical role in the qualification, or requalification, of a facility. There
are several areas where this is especially true:
-
Cleaning Studies
-
Contamination control planning (see
PMF News v13 n6)
-
Equipment Hold Time Studies (establishment of both clean and dirty
hold times)
-
Selection of sample sites for environmental monitoring.
-
Establishment of alert and action limits
This article will focus on the selection of the sample sites as this
issue causes a great deal of confusion in the field. This is not meant to
describe the only possible approach to this selection but rather one that
the author has used in the past. Due to the limitations of space this
discussion will not include sampling of the water system, gasses or
personnel (all important topics to be dealt with in later articles).
The number of sites to evaluate during a qualification study breaks down
by test type and surface:
-
Non-viable air
-
Active sampling of air-borne viables
-
Passive sampling of air-borne viable (settle plates)
-
Surface sampling—Walls & Floors
-
Surface Sampling—Equipment
Number of
Sites for Qualification Studies
ISO 14644-1 describes a method to determine the number of
sampling sites for site qualification.
Annex B states that we should determine the
minimum number of sample sites
by the equation:
NL =
ÖA
Where
N L
is the minimum number of sampling locations (rounded up to a whole number);
and
A is the area of the clean room or zone in meters2
This might work well enough for non-viable
particulate measures (which, after all is the intent and scope of 14644-1)
but we also wish to consider viable air sampling (both passive and active),
and viable surface monitoring.
Let’s make this a bit easier and argue that both viable and
non-viable active air sampling sites should be done at the same location (or
as close as practical to avoid compromising the other measure, or the
integrity of the product).
Therefore the number of active air sampling sites is driven by the
non-viable particulate calculation.
Passive air sampling (settle plates), are a
frequently-used measure of clean room (or zone) control.
They have the several advantages in this regard, chief among them the
ability to remain in continuous exposure for up to 4 hours (exposure time
must be demonstrated) and they are not disruptive to the immediate
environment and so may possibly sample sites very near product exposure
points (see Whyte, 1996 for a discussion of these, and other , advantages).
In addition, they are not as prone to variation among different
vendors as are active samplers (Yao and Mainelis 2006).
However, it is not clear how to interpret the data in all cases from
areas of laminar air flow at the rates used for modern clean rooms.
However you view their usefulness, the current international
regulatory expectation for air monitoring includes their use and the
justification of sampling sites.
A prudent measure is to use the same number of sampling sites for settle
plates as used for the active viable and non-viable sampling programs.
These will not be the same sites, but similar in number.
Remember, we are not talking about the sample sites for
the on-going environmental monitoring program, but rather the qualification
of the sample sites to be used in that routine program.
This leaves us with determination of the number of surface
sampling sites for the qualification study. There is no regulatory guidance
directed to this point for the international pharmaceutical industry (even
PIC/S, which generally can be counted on to provide details on almost
everything microbiological, is silent on this point – PIC/S 2004). Also
silent on this point is the PDA (Parenteral Drug Association) Technical
Report #13. We are left to our own devices. One approach to determination of
the number of sites would be to address it in an manner similar to that of
ISO 14644-1 for the walls and floors (as relevant). Each surface would then
be treated as a separate item and the minimum number of sites determined for
each as the square root of its surface area.
This leaves us with only the question of how to determine
the number of surface sampling sites for equipment. This cannot be answered
by this approach convincingly (in my opinion). This determination, quite
frankly, may well be something that must be left to each facility as the
numbers could be driven by the nature of the equipment and as well as the
associated manufacturing process.
Having determined the number of sites for each room, we
now need to determine their location.
Selection of Sample Sites
Here the PDA Technical Report provides some useful guidance:
“Factors to consider in selecting sites for routine surveillance are:
-
At which sites would microbial contamination most likely have an adverse
effect on product quality?
-
What sites would most likely demonstrate heaviest microbial
proliferation during actual production?
-
Should site
selection involve a statistical design (e.g.,following the calculations
in Federal Standard 209E) or should site selection be made on the basis
of grid profiling? Should some sites for routine monitoring be rotated?
[Note from author:
As 209e has been withdrawn in favor of ISO 14644, the answer is
No]
-
What sites would
represent the most inaccessible or difficult areas to clean, sanitize,
or disinfect?
-
What activities
in the area contribute to the spread of contamination?
-
Would the act of
sampling at a given site disturb the environment sufficiently to cause
erroneous data to be collected or contaminate product?”
The FDA Aseptic Processing Guidance document (FDA 2004) also provides some
guidance in section IVA:
“Air in the immediate
proximity of exposed sterilized containers/closures and filling/ closing
operations would be of appropriate particle quality when it has a
per-cubic-meter particle count of no more than 3520 in a size range of 0.5
μm and larger when counted at representative locations normally not more
than 1 foot away from the work site, within the airflow, and during
filling/closing operations. This level of air cleanliness is also known as
Class 100 (ISO 5).
We recommend that measurements to confirm air cleanliness in critical areas
be taken at sites where there is most potential risk to the exposed
sterilized product, containers, and closures. The particle counting probe
should be placed in an orientation demonstrated to obtain a meaningful
sample. Regular monitoring (Continued from page 3) should be performed
during each production shift. We recommend conducting nonviable particle
monitoring with a remote counting system. These systems are capable of
collecting more comprehensive data and are generally less invasive than
portable particle counters. See Section X.E. for additional guidance on
particle monitoring.
Some operations can
generate high levels of product (e.g., powder) particles that, by their
nature, do not pose a risk of product contamination. It may not, in these
cases, be feasible to measure air quality within the one-foot distance and
still differentiate background levels of particles from air contaminants. In
these instances, air can be sampled in a manner that, to the extent
possible, characterizes the true level of extrinsic particle contamination
to which the product is exposed. Initial qualification of the area under
dynamic conditions without the actual filling function provides some
baseline information on the non-product particle generation of the
operation.”
Further on in Section XA we read:
“Sample timing, frequency, and location should be carefully selected based
upon their relationship to the operation performed…
It is important that locations posing the most microbiological risk to the
product be a key part of the program. It is especially important to monitor
the microbiological quality of the critical area to determine whether or not
aseptic conditions are maintained during filling and closing activities. Air
and surface samples should be taken at the locations where significant
activity or product exposure occurs during production. Critical surfaces
that come in contact with the sterile product should remain sterile
throughout an operation. When identifying critical sites to be sampled,
consideration should be given to the points of contamination risk in a
process, including factors such as difficulty of setup, length of processing
time, and impact of interventions.”
The EU guidance document
“Manufacture of Sterile Medicinal Products” (EU 2008) provides some site
selection guidance: “18. Where aseptic
operations are performed monitoring should be frequent using methods such as
settle plates, volumetric air and surface sampling (e.g. swabs and contact
plates). Sampling methods used
in operation should not interfere with zone protection.”
Similarly, guidance in the most recently proposed revision to USP chapter
<1116> (USP 2007) is of general interest:
“Microbiological
sampling sites are best selected when human activity during manufacturing
operations are considered. Careful observation and mapping of a clean room
during the qualification phase can provide information concerning the
movement and positioning of personnel within these rooms. Such observation
can also yield important information about the most frequently conducted
manipulations and interventions.
Other areas of
concern relative to introduction of contamination into clean rooms are at
entry points where equipment and materials move from areas of lower
classification to those of higher classification. Therefore, areas within
and around doors and airlocks should be included in the monitoring scheme.”
Let’s summarize some specific considerations of sample site selection for
the qualification study.
After we determine the minimal number of sites in a room, we have to
determine their most useful location. This determination should be
documented in a written justification and should consider:
-
Contamination vectors (handles, control panels, doors, etc).
-
High traffic areas
-
Personnel flow
-
Material flow
-
Waste Flow
-
Surfaces that are difficult to disinfect
-
HVAC (primarily returns in this regard)
-
Product risk
-
Extent of product exposure
-
The type of activity performed near that site
-
The Potential for Contaminations from Interventions and manipulations
-
Contamination vectors
Selection of Routine Sites After the
Qualification Study
The qualification study should include sufficient
replicates under conditions both “at rest” and “dynamic” to allow
identification of sites that provide useful information. It should be
clarified that the term “useful information” is not meant to describe “those
sites that give the most desireable counts” but rather those sites which
either give the highest counts (ie serve as the most sensitive measure of
the state of control of the room) or were shown to be appropriately placed
to herald a problem in the room. The number of sites in a room or zone
should similarly be driven by data generated during this study. Both the
number and location of sites or each clean room or zone should be justified
in the report from this qualification study.
The following section (X.1.A) from the FDA guidance is
relevant for consideration here:
“All environmental monitoring locations should be
described in SOPs with sufficient detail to allow for reproducible sampling
of a given location surveyed. Written SOPs should also address elements such
as (1) frequency of sampling, (2) when the samples are taken (i.e., during
or at the conclusion of operations), (3) duration of sampling, (4) sample
size (e.g., surface area, air volume), (5) specific sampling equipment and
techniques, (6) alert and action levels, and (7) appropriate response to
deviations from alert or action levels.
A
Note on the “Microorganism Catalog”
The FDA has clearly recommended establishment of a
listing of common microorganisms found in the aseptic manufacturing
environment. This expectation is laid out in section X.B. (FDA 2004).
“Characterization of recovered microorganisms provides vital information for
the environmental monitoring program. Environmental isolates often correlate
with the contaminants found in a media fill or product sterility testing
failure, and the overall environmental picture provides valuable information
for an investigation. Monitoring critical and immediately surrounding clean
areas as well as personnel should include routine identification of
microorganisms to the species (or, where appropriate, genus) level. In some
cases, environmental trending data have revealed migration of microorganisms
into the aseptic processing room from either uncontrolled or lesser
controlled areas. Establishing an adequate program for differentiating
microorganisms in the lesser-controlled environments, such as Class 100,000
(ISO 8), can often be instrumental in detecting such trends. At minimum, the
program should require species (or, where appropriate, genus) identification
of microorganisms in these ancillary environments at frequent intervals to
establish a valid, current database of contaminants present in the facility
during processing (and to demonstrate that cleaning and sanitization
procedures continue to be effective).”
The EM qualification study is an excellent opportunity to start this
catalog, and to generate information on the effectiveness of the cleaning
and sanitization program from a microbiological perspective.
References
EU.
2008. EudraLex The Rules
Governing Medicinal Products in the European Union Volume 4:
EU Guidelines to Good Manufacturing Practice Medicinal Products for
Human and Veterinary Use: Annex
1 Manufacture of Sterile Medicinal Products.
PIC/S.
2004. PI-006-2
Recommendations on Validation Master Plan, Installation and
Operational Qualification, Non-sterile Process Validation, Cleaning
Validation
PDA. 2001.
PDA Tech Report #13 (Revised): Fundamentals of an Environmental
Monitoring Program
PMF News v13 n6
http://microbiologyforum.org/PMFNews/PMFNews.13.06.0706.pdf
USP. 2007. <1116> Microbiological Control and Monitoring Environments Used
for the Manufacture of Healthcare Products Pharm Forum.
33(3).
Whyte, W. 1996. In Support of Settle Plates. PDA J
Pharm Sci Tech. 50(4):201-204.
Yao, M. and Mainelis, G. 2006. Investigation of Cut-Off
Sizes and Collection Efficiencies of Portable Microbial Samplers. Aerosol
Sci Technol. 40:595 – 606.
Consulting with Scott Sutton Go to top of page |